Research Paper Volume 13, Issue 20 pp 23672—23688

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma


Figure 4. Validation of signature genes in patients with metastatic cutaneous melanoma undergoing chemotherapy and immunotherapy. (A and B) Western blot results of signature genes and t-test comparison results of gray values between the two groups. (C) T-test comparison results of the relative expression levels of signature genes in real-time qPCR between the two groups. (D) Hematoxylin-eosin (HE) staining: normal skin tissue, tumor tissues of metastatic melanoma patients receiving chemotherapy and immunotherapy. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.